Relapsed Plasmablastic Lymphoma in an HIV-Infected Patient—Experience of High-Dose Chemotherapy with Autologous Stem Cell Rescue: A Case Report with Review of Literature

Abstract

Plasmablastic lymphoma (PBL) is a subtype of non-Hodgkin lymphoma with dismal outcome despite multidrug chemotherapy regimen leading to high rates of disease recurrence. High-dose chemotherapy with autologous stem cell rescue (HDCT/ASCR) is an effective salvage therapy in patients with chemo-sensitive human immunodeficiency virus (HIV)-associated non-Hodgkin lymphoma. We report a case of 38 years old male with relapsed PBL associated with underlying HIV infection, who underwent HDCT/ASCR. He presented with low-grade fever and abdominal discomfort. He was evaluated with fluorodeoxyglucose positron emission tomography scan followed by omental biopsy that confirmed disease relapse. He received second-line therapy containing bortezomib and daratumumab and achieved remission (CR2). Subsequently, he underwent HDCT/ASCR. He has been clinically asymptomatic in good general condition having disease-free survival of 18 months after HDCT/ASCR. Our objective of presenting this case report is its complexity from presentation, diagnosis, and treatment. We take this opportunity to review the epidemiology and clinicopathological characteristics of PBL, as well as discuss the advancements in therapeutic options of this challenging disease.

Keywords

plasmablastic lymphoma - HIV infection - combined antiretroviral therapy - autologous stem cell transplant

Ethics

The ethics committee approval for publication (ECC/ONCO/June/28, dated: 28/06/2021) was obtained from Jaslok Hospital and Research Centre institutional ethics committee.

Publikationsverlauf

Artikel online veröffentlicht:
18. April 2022

• References

• 1 Zuze T, Painschab MS, Seguin R. et al. Plasmablastic lymphoma in Malawi. Infect Agent Cancer 2018; 13: 22
• 2 Broccoli A, Nanni L, Stefoni V. et al. A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report. BMC Cancer 2018; 18 (01) 645
• 3 Al-Malki MM, Castillo JJ, Sloan JM, Re A. Hematopoietic cell transplantation for plasmablastic lymphoma: a review. Biol Blood Marrow Transplant 2014; 20 (12) 1877-1884
• 4 Grimm KE, O'Malley DP. Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues. Ann Diagn Pathol 2019; 38: 6-10
• 5 Castillo JJ, Winer ES, Stachurski D. et al. HIV-negative plasmablastic lymphoma: not in the mouth. Clin Lymphoma Myeloma Leuk 2011; 11 (02) 185-189
• 6 Delecluse HJ, Anagnostopoulos I, Dallenbach F. et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood 1997; 89 (04) 1413-1420
• 7 Schichman SA, McClure R, Schaefer RF, Mehta P. HIV and plasmablastic lymphoma manifesting in sinus, testicles, and bones: a further expansion of the disease spectrum. Am J Hematol 2004; 77 (03) 291-295
• 8 Tchernonog E, Faurie P, Coppo P. et al. Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group. Ann Oncol 2017; 28 (04) 843-848
• 9 Castillo JJ, Winer ES, Stachurski D. et al. Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma. Leuk Lymphoma 2010; 51 (11) 2047-2053
• 10 Castillo JJ, Winer ES, Stachurski D. et al. Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma. Oncologist 2010; 15 (03) 293-299
• 11 Zelenetz AD, Gordon LI, Wierda WG. et al. Diffuse large B-cell lymphoma version 1.2016. J Natl Compr Canc Netw 2016; 14 (02) 196-231
• 12 Cortes J, Thomas D, Rios A. et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 2002; 94 (05) 1492-1499
• 13 Patel K, Feng L, Oki Y. et al. Plasmablastic lymphoma: 28 patient single institution experience. Blood 2013; 122 (21) 4310
• 14 Barta SK, Lee JY, Kaplan LD, Noy A, Sparano JA. Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma. Cancer 2012; 118 (16) 3977-3983
• 15 Castillo JJ, Bibas M, Miranda RN. The biology and treatment of plasmablastic lymphoma. Blood 2015; 125 (15) 2323-2330
• 16 Yordanova K, Stilgenbauer S, Bohle RM. et al. Spontaneous regression of a plasmablastic lymphoma with MYC rearrangement. Br J Haematol 2019; 186 (06) e203-e207
• 17 Montes-Moreno S, Martinez-Magunacelaya N, Zecchini-Barrese T. et al. Plasmablastic lymphoma phenotype is determined by genetic alterations in MYC and PRDM1. Mod Pathol 2017; 30 (01) 85-94
• 18 Holderness BM, Malhotra S, Levy NB, Danilov AV. Brentuximab vedotin demonstrates activity in a patient with plasmablastic lymphoma arising from a background of chronic lymphocytic leukemia. J Clin Oncol 2013; 31 (12) e197-e199
• 19 Palumbo A, Chanan-Khan A, Weisel K. et al; CASTOR Investigators. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 2016; 375 (08) 754-766
• 20 Dimopoulos MA, Oriol A, Nahi H. et al; POLLUX Investigators. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016; 375 (14) 1319-1331
• 21 Laurent C, Fabiani B, Do C. et al. Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients. Haematologica 2016; 101 (08) 976-984
• 22 Delmore JE, Issa GC, Lemieux ME. et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146 (06) 904-917
• 23 Mine S, Hishima T, Suganuma A. et al. Interleukin-6-dependent growth in a newly established plasmablastic lymphoma cell line and its therapeutic targets. Sci Rep 2017; 7 (01) 10188
• 24 Perrine SP, Hermine O, Small T. et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 2007; 109 (06) 2571-2578
• 25 Castillo JJ, Reagan JL, Bishop KD, Apor E. Viral lymphomagenesis: from pathophysiology to the rationale for novel therapies. Br J Haematol 2014; 165 (03) 300-315
• 26 Re A, Michieli M, Casari S. et al. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood 2009; 114 (07) 1306-1313
• 27 Re A, Cattaneo C, Michieli M. et al. High-dose therapy and autologous peripheral-blood stem-cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapy. J Clin Oncol 2003; 21 (23) 4423-4427
• 28 Liu JJ, Zhang L, Ayala E. et al. Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: a single institutional experience and literature review. Leuk Res 2011; 35 (12) 1571-1577
• 29 Holland HK, Saral R, Rossi JJ. et al. Allogeneic bone marrow transplantation, zidovudine, and human immunodeficiency virus type 1 (HIV-1) infection. Studies in a patient with non-Hodgkin lymphoma. Ann Intern Med 1989; 111 (12) 973-981
• 30 Hamadani M, Devine SM. Reduced-intensity conditioning allogeneic stem cell transplantation in HIV patients with hematologic malignancies: yes, we can. Blood 2009; 114 (12) 2564-2566